GlassScriptPhysician profile
Brandon M Peters
NPI 1487757035
$11,752.88
in general payments reported to CMS, 2019-2025
39 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,096 · 2020: $1,677 · 2021: $1,514 · 2022: $1,671 · 2023: $1,459 · 2024: $1,251 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,794.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,814.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,780.78 | 2019-2025 | Farxiga, Breztri, Tagrisso |
| Amgen INC. | $970.22 | 2019-2024 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $934.35 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $888.52 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $740.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $486.80 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $483.73 | 2019-2025 | |
| Astellas Pharma US INC | $452.26 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $415.64 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $389.25 | 2019-2022 | |
| Pfizer INC. | $349.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $312.73 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $232.03 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $200.67 | 2023 | Quviviq |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.